Figure 2
Kinetics of JAK2 mutations in a patient who received DLI for persistence of JAK2 mutation. Due to persistence of JAK2-V617F–positive cells, patient 20 received 1 × 106 CD3+ cells/kg as DLI. He experienced mild GVHD and became JAK2-V617F negative, but relapsed 1 year after DLI.
